Fusion Pharmaceuticals, a clinical-stage precision oncology company has announced an investment commitment of up to US$20 million from the Canada Pension Plan Investment Board. The financing will be primarily used to expand the use of the company’s proprietary linker technology platform and to advance its lead asset, currently in a Phase 1 trial for treating solid tumours.